Blood-Related Cancers

New cancer target may hold promise in treating lymphoma and leukemia

Published in Cancer Weekly, September 3rd, 2002

At the 31st annual meeting of the International Society for Experimental Hematology held in Montreal, Canada, scientists from Cell Therapeutics, Inc., (CTIC) presented preclinical results that examined the effects of CT-32228, a first generation small molecule inhibitor of lysophosphatidic acid acyltransferase-B (LPAAT-B), on lymphoma and leukemia cells.

Current antilymphoma and leukemic therapies destroy normal bone marrow cells and suppress the immune system. However, this preclinical study demonstrates that CT-32228 inhibition of LPAAT selectively destroyed only the cancerous cells leaving the immune system cells unaffected.

"These provocative...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-09-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry

Search our medical news database